B. Riley Securities Initiates Coverage On Arcturus Therapeutics with Buy Rating, Announces Price Target of $22

Benzinga Newsdesk www.benzinga.com Neutral 61.0%

Neg 0% Neu 61% Pos 0%

B. Riley Securities analyst Mayank Mamtani initiates coverage on Arcturus Therapeutics (NASDAQ:ARCT) with a Buy rating and announces Price Target of $22.